H.C. Wainwright reiterates buy rating on Anixa Biosciences stock

Anixa Biosciences (ANIX) has advanced its Phase 1 CAR-T therapy trial for ovarian cancer, dosing the first patient in the fourth cohort at a significantly increased level of 3x10^6 cells/kg. This progression follows the absence of dose-limiting toxicity in the three prior dose-escalation cohorts, enabling further dose escalation and suggesting a favorable safety profile. H.C. Wainwright maintained its Buy rating and $7.00 price target, underscoring the significance of this clinical milestone for Anixa's valuation and its outlook within the rapidly evolving oncology sector.

Analysis

Anixa Biosciences (ANIX) has reached a significant milestone in its Phase 1 trial for its CAR-T therapy in ovarian cancer, prompting H.C. Wainwright to maintain its Buy rating and a $7.00 price target. The company progressed to the fourth cohort, administering a dose of 3x10^6 cells/kg, a notable escalation from the 1x10^6 cells/kg in the previous cohort. This advancement was critically enabled by the absence of any dose-limiting toxicity in the third cohort, indicating a favorable safety profile for the therapy thus far. The trial's progression through increasing dose levels is a key de-risking event for the clinical-stage company. Furthermore, a February 2025 protocol amendment, approved with partner Moffitt Cancer Center, expands the trial's potential by allowing for a second dose in benefiting patients and broadening enrollment to include other tumor types, such as sex cord stromal and Sertoli-Leydig cell tumors.

Key Decisions for Investors

• The successful dose escalation without observed toxicity is a significant de-risking event for Anixa's CER-T platform, reinforcing the bullish thesis for a clinical-stage asset.
• Investors should closely monitor for forthcoming safety and any preliminary efficacy data from this higher-dose fourth cohort, as this will serve as the next major clinical catalyst.
• The recent protocol amendment to include additional tumor types and allow for potential re-dosing could expand the therapy's addressable market, a factor to consider in long-term valuation models.
• The maintained $7.00 price target from H.C. Wainwright provides a specific valuation benchmark that can be used to assess the potential upside following this positive clinical development.